S. 2620 · 119th Congress
REMEDY Act
S. 2620 limits brand-name drug makers to selecting a single patent eligible to trigger automatic delays in generic drug approvals.
Where it is in the process
Latest action: Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (text: CR S5000)
Most bills die quietly in committee — clearing it is the single biggest hurdle legislation faces. See how a bill becomes law for the full path this bill still has to travel, or check the official record on Congress.gov for the latest.
What it costs
No CBO estimate yet.
The Congressional Budget Office usually scores a bill only after it clears committee, so an early-stage bill having no official number is normal — we report that honestly rather than guess. Here's how CBO cost estimates work and what the deficit number actually means.
Pass it, or trash it?
This bill was featured in the daily poll on @passortrash, where followers vote Pass or Trash on one real bill a day. Covered on 2026-07-02.